A carregar...
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutioni...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492664/ https://ncbi.nlm.nih.gov/pubmed/26170619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S69433 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|